Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Overview of attention for article published in Clinical Cancer Research, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#19 of 17,842)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 56 news outlets
policy: 1 policy source

twitter: 23 X users
guideline: 1 clinical guideline source

Readers on

mendeley: 28 Mendeley

So far, Altmetric has seen 27 X posts from 23 X users, with an upper bound of 51,989 followers.

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study https://t.co/Mty0sHeOF4 #hvhebron #onco [Text complet]

RT @CCR_AACR: Phase 3 Study: Efficacy of ripretinib against range of KIT/PDGFRA mutations (INVICTUS Study). https://t.co/GzmkYVvyue https:/…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 23 additional X posts.